Literature DB >> 15149747

Prognostic value of multifocality on progression and survival in localized renal cell carcinoma.

Hervé Lang1, Véronique Lindner, Mael Martin, Hervé Letourneux, Catherine Roy, Christian Saussine, Didier Jacqmin.   

Abstract

OBJECTIVE: Incidence of multifocality in Renal Cell Carcinoma (RCC) is estimated at between 5 and 25%. Multifocality has been largely studied because of the growing interest in conservative surgery which is a risk of local recurrence. The aim of this study is to evaluate the relationship between multifocality and other prognostic parameters and whether it is an independent prognostic factor.
MATERIAL AND METHODS: From 1980 to 1990, 255 patients (median age: 60.9 years) were treated by radical nephrectomy for pT1 to pT3b N0M0 RCC. The median follow-up time was 183 months. Multifocality was defined as the existence of at least one other tumoral localization, macroscopically and microscopically diagnosed as renal cell carcinoma, in the same kidney. Studied parameters were: age, sex, side, size, stage, Fuhrman's grade, capsular invasion, renal vein involvement and microvascular invasion. Survival was assessed with Kaplan-Meier and Cox models.
RESULTS: 37 cases of multifocal RCC were diagnosed (14.5%). There was only a significant correlation with stage (p=0.002) and with capsular invasion (p=0.002). No other factor was correlated with multifocality. It had no influence on the risk of metastatic progression, overall or specific survival.
CONCLUSION: There is a significant correlation between capsular invasion and multifocality that has to be considered before proposing conservative surgery for a localized RCC. Multifocality has no influence on survival or metastatic progression in case of radical nephrectomy.

Entities:  

Mesh:

Year:  2004        PMID: 15149747     DOI: 10.1016/j.eururo.2004.02.006

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  9 in total

Review 1.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

2.  Partial and Radical Nephrectomy for Unilateral Synchronous Multifocal Renal Cortical Tumors.

Authors:  Roy Mano; Matthew Kent; Yaniv Larish; Andrew G Winer; Michael S Chevinsky; Abraham Ari Hakimi; Itay A Sternberg; Daniel D Sjoberg; Paul Russo
Journal:  Urology       Date:  2015-04-11       Impact factor: 2.649

Review 3.  [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].

Authors:  M Staehler; N Haseke; G Schöppler; T Stadler; G Heinemann; C G Stief
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

Review 4.  The role of minimally invasive surgery in multifocal renal cell carcinoma.

Authors:  Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  Curr Urol Rep       Date:  2012-06       Impact factor: 3.092

5.  Ipsilateral synchronous papillary and clear renal cell carcinoma: A case report and review of literature.

Authors:  Jing Yin; Mo Zheng
Journal:  World J Clin Cases       Date:  2022-06-06       Impact factor: 1.534

Review 6.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

7.  Ipsilateral synchronous clear and papillary renal cell carcinoma: A case report and review of the literature.

Authors:  Muna Alhusban; Sohaib Alhamss; Bayan Alzumaili; Ali Al-Daghmin
Journal:  Urol Case Rep       Date:  2017-11-23

8.  Multifocal renal cell carcinoma: clinicopathologic features and outcomes for tumors </=4 cm.

Authors:  Paul L Crispen; Christine M Lohse; Michael L Blute
Journal:  Adv Urol       Date:  2008

9.  Robotic-assisted partial nephrectomy with sequential clamping of segmental renal arteries for multiple ipsilateral renal tumors: initial outcomes.

Authors:  Jie Yang; Jia-Dong Xia; Jian-Xin Xue; Ning-Hong Song; Chao Liang; Di Xi; Ya-Min Wang; Zeng-Jun Wang
Journal:  BMC Urol       Date:  2019-05-03       Impact factor: 2.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.